1 / 29

Natural History of Atherothrombosis

Natural History of Atherothrombosis. Finding the Right Risk-Benefit Balance. Outcomes in Patients With Atherosclerotic Vascular Disease. CHARISMA Study Primary Efficacy Results (MI/Stroke/CV Death) by Prespecified Entry Category.

teagan-miller
Download Presentation

Natural History of Atherothrombosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Natural History of Atherothrombosis

  2. Finding the Right Risk-Benefit Balance

  3. Outcomes in Patients With Atherosclerotic Vascular Disease

  4. CHARISMA StudyPrimary Efficacy Results (MI/Stroke/CV Death) by Prespecified Entry Category

  5. MonotherapyClopidogrel vs Aspirin in Patients at Risk for Ischemic Events (CAPRIE)

  6. REACH Data

  7. Long-Term Dual Antiplatelet Therapy After MI?

  8. TRILOGY ACS Post Hoc Analysis

  9. Why Not Treat Everyone WithLong-Term Thienopyridine Therapy?

  10. Central Role of Thrombin as a Mediator of Coagulation and Platelet Thrombosis

  11. PAR-1 Antagonists

  12. TRA (Vorapaxar) ProgramEvaluation of Efficacy and Safety in Acute and Chronic Atherothrombosis

  13. TRA-CER TrialVorapaxar in ACS

  14. TRA 2◦P-TIMI 50Safety and Efficacy at 3 Years

  15. TRA 2◦P-TIMI 50MI Subgroup at 3 Years

  16. Patients Considered for Long-Term, Higher Potency Antiplatelet Therapy

  17. Addition of Vorapaxar

  18. TRA◦2P-TIMI 50Peripheral Artery Disease Cohort

  19. DAPT Study Design

  20. PEGASUS-TIMI 54 Trial

  21. Take-home Points and Summary

  22. Abbreviations

  23. Abbreviations (cont)

  24. References

  25. References (cont)

  26. References (cont)

  27. References (cont)

More Related